CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsAltman Z-Score -4.62: distress zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
617.83MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.4610xvs all stocks
52-Week Change
45.20%vs all stocks
Market Capitalization
617.83MUSDvs all stocks (USD)
Enterprise Value
469.96MUSDvs all stocks (USD)
Forward P/E
-2.78xvs Biotechnology peers
Price to Book (MRQ)
1.67xvs Biotechnology peers
Enterprise to EBITDA
-2.67xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-25.97%vs Biotechnology peers
Return on Equity (TTM)
-52.32%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 17, 2026Gross Profit (TTM)
-131.96MUSDvs all stocks (USD)
EBITDA (TTM)
-175.70MUSDvs all stocks (USD)
Net Income (TTM)
-173.76MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-109.23MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-69.94MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 17, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-206.93MUSDvs all stocks (USD)
Pre-tax Income
-190.89MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-190.89MUSDFY2025 · Dec 31, 2025EBIT
-189.81MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-175.07MUSDFY2025 · Dec 31, 2025Research & Development
150.15MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
56.78MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
19.29MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
1.07MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-190.89MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-148.13MUSDFY2025 · Dec 31, 2025Free Cash Flow
-148.51MUSDDerived from operating cash flow minus capital expenditure. This filing charges 12.36M of depreciation against 386K of capital expenditure, and its own free-cash-flow line reads -149.63M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
61.98MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-190.89MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
12.36MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
0.00USDFY2025 · Dec 31, 2025Stock-based Compensation
37.64MUSDFY2025 · Dec 31, 2025Other Non-cash Items
4.36MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-1.23MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-10.36MUSDFY2025 · Dec 31, 2025Capital Expenditures
-386.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-138.26MUSDFY2025 · Dec 31, 2025Sale of Investments
234.20MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
95.56MUSDFY2025 · Dec 31, 2025Other Financing Charges
6.91MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
29.26MUSDFY2025 · Dec 31, 2025Shares Outstanding
244.82MSharesUpdated Jul 17, 2026Shares Short
63.39MSharesUpdated Jul 17, 2026Short Ratio
6.35daysvs all stocks
Short % of Shares Outstanding
20.32%vs all stocks
% Held by Insiders
11.04%vs all stocks
% Held by Institutions
53.65%vs all stocks
Total Cash (MRQ)
266.89MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.7730USDUpdated Jul 17, 2026Total Debt (MRQ)
81.05MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.2906xvs Biotechnology peers
Current Ratio (MRQ)
9.65xvs Biotechnology peers
Book Value per Share (MRQ)
1.14USDUpdated Jul 17, 2026Total Assets
415.90MUSDvs all stocks (USD)
Total Current Assets
257.75MUSDFY2025 · Dec 31, 2025Total Liabilities
123.36MUSDFY2025 · Dec 31, 2025Total Non-current Assets
158.16MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
90.85MUSDFY2025 · Dec 31, 2025Total Current Liabilities
32.51MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
51.69MUSDFY2025 · Dec 31, 2025Other Short-term Investments
198.52MUSDFY2025 · Dec 31, 2025Accounts Payable
4.27MUSDFY2025 · Dec 31, 2025Short-term Debt
8.21MUSDFY2025 · Dec 31, 2025Long-term Debt
75.05MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
15.80MUSDFY2025 · Dec 31, 2025Common Stock (Book)
229.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-2.01BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
292.54MUSDvs all stocks (USD)
52-Week Low
0.9800USDUpdated Jul 17, 202652-Week High
4.46USDUpdated Jul 17, 202652-Week Change
45.20%vs all stocks
Beta
0.4610xvs all stocks
50-Day MA
2.06USDUpdated Jul 17, 2026200-Day MA
1.83USDUpdated Jul 17, 2026Avg 10-Day Volume
9.45MSharesUpdated Jul 17, 2026Avg 30-Day Volume
9.85MSharesUpdated Jul 17, 2026Diluted EPS (TTM)
-0.7900USDUpdated Jul 17, 2026Other Income / Expense
-2.17MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Diagnostic
High Equity Share With Elevated Lease Share of Assets
Little debt against its assets, but leases are a large share of what it holds.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 9.65Altman Z-Score: -4.62
Financial Health
Altman Z-Score -4.62: distress zoneCritical
Altman Z-Score: -4.62
Low earnings qualitySignificant
Earnings Quality Score: -0.56
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing Scitop Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
TTY Biopharm Company Limited
Tier 1ProductionApproval-Gated PipelineRule
Kexing Biopharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou AGS Medtech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tectonic Therapeutic Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hainan Shuangcheng Pharmaceuticals Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tibet Weixinkang Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jinhe Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Achieve Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Kinetic Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Lyell Immunopharma, Inc.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityHigh Equity Share With Elevated Lease Share of Assets
Nanjing Xinjiekou Department Store Co. Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Halo Microelectronics Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity